A COST-EFFECTIVESS ANALYSIS OF TRASTUZUMAB EMTANSINE VERSUS TRASTUZUMAB FOR THE ADJUVANT TREATMENT OF PATIENTS WITH RESIDUAL INVASIVE HER2-POSITIVE BREAST CANCER IN PORTUGAL

被引：0
|
作者：
Silva Miguel, L. [1 ]
Pinheiro, B. [1 ]
Lopes, R. [1 ]
Revil, C. [2 ]
Monteiro, I [3 ]
Borges, M. [4 ]
机构：
[1] Univ Lisbon, Ctr Estudos Med Baseada Evidencia, Fac Med, Lisbon 11, Portugal
[2] F Hoffmann La Roche Ltd, Basel, Switzerland
[3] Roche Farmaceut Quim Lda, Amadora, Portugal
[4] Univ Lisbon, Lab Farmacol Clin & Terapeut, Fac Med, Lisbon, Portugal
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 01期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
POSB51
引用
收藏
页码：S69 / S70
页数：2
相关论文
共 50 条
  • [41] NICE guidance on trastuzumab emtansine for HER2-positive advanced breast cancer
    Elsada, Ahmed
    Doss, Sally
    Robertson, Janet
    Adam, E. Jane
    LANCET ONCOLOGY, 2016, 17 (02): : 143 - 144
  • [42] FDA Approval Summary: Ado-Trastuzumab Emtansine for the Adjuvant Treatment of HER2-positive Early Breast Cancer
    Wedam, Suparna
    Fashoyin-Aje, Lola
    Gao, Xin
    Bloomquist, Erik
    Tang, Shenghui
    Sridhara, Rajeshwari
    Goldberg, Kirsten B.
    King-Kallimanis, Bellinda L.
    Theoret, Marc R.
    Ibrahim, Amna
    Amiri-Kordestani, Laleh
    Pazdur, Richard
    Beaver, Julia A.
    CLINICAL CANCER RESEARCH, 2020, 26 (16) : 4180 - 4185
  • [43] Trastuzumab emtansine (T-DM1) for the treatment of HER2-positive breast cancer
    Sliwkowski, Mark X.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2011, 242
  • [44] Trastuzumab Emtansine: A Review of Its Adjuvant Use in Residual Invasive HER2-Positive Early Breast Cancer (vol 80, pg 1723, 2020)
    Lyseng-Williamson, Katherine A.
    DRUGS, 2020, 80 (18) : 2001 - 2001
  • [45] Safety Evaluation of Trastuzumab Emtansine in Japanese Patients with HER2-Positive Advanced Breast Cancer
    Watanabe, Junichiro
    Ito, Yoshinori
    Saeki, Toshiaki
    Masuda, Norikazu
    Takano, Toshimi
    Takao, Shintaro
    Nakagami, Kazuhiko
    Tsugawa, Koichiro
    Nakagawa, Shintaro
    Kanatani, Kazumitsu
    Nakayama, Takahiro
    IN VIVO, 2017, 31 (03): : 493 - 500
  • [46] Cost-effectiveness of ado-trastuzumab emtansine (T-DM1) versus trastuzumab (H) for the adjuvant treatment of patients with residual invasive HER2+early breast cancer in the US
    Goertz, Hans-Peter
    Herrera-Restrepo, Oscar
    Wehler, Elizabeth
    Bilir, Pinar
    Antao, Vincent
    Jhuti, Gurleen Singh
    CANCER RESEARCH, 2020, 80 (04)
  • [47] Trastuzumab emtansine in the treatment of HER-2-positive metastatic breast cancer patients
    Bighin, Claudia
    Pronzato, Paolo
    Del Mastro, Lucia
    FUTURE ONCOLOGY, 2013, 9 (07) : 955 - 957
  • [48] FDA Approval: Ado-Trastuzumab Emtansine for the Treatment of Patients with HER2-Positive Metastatic Breast Cancer
    Amiri-Kordestani, Laleh
    Blumenthal, Gideon M.
    Xu, Qiang Casey
    Zhang, Lijun
    Tang, Shenghui W.
    Ha, Linan
    Weinberg, Wendy C.
    Chi, Bo
    Candau-Chacon, Reyes
    Hughes, Patricia
    Russell, Anne M.
    Miksinski, Sarah Pope
    Chen, Xiao Hong
    McGuinn, W. David
    Palmby, Todd
    Schrieber, Sarah J.
    Liu, Qi
    Wang, Jian
    Song, Pengfei
    Mehrotra, Nitin
    Skarupa, Lisa
    Clouse, Kathleen
    Al-Hakim, Ali
    Sridhara, Rajeshwari
    Ibrahim, Amna
    Justice, Robert
    Pazdur, Richard
    Cortazar, Patricia
    CLINICAL CANCER RESEARCH, 2014, 20 (17) : 4436 - 4441
  • [49] Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer
    Douchet, G.
    Richard, Sandrine
    ONCOLOGIE, 2018, 20 (01) : 43 - 44
  • [50] Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
    Piccart-Gebhart, MJ
    Procter, M
    Leyland-Jones, B
    Goldhirsch, A
    Untch, M
    Smith, I
    Gianni, L
    Baselga, J
    Bell, R
    Jackisch, C
    Cameron, D
    Dowsett, M
    Barrios, CH
    Steger, G
    Huang, CS
    Andersson, M
    Inbar, M
    Lichinitser, M
    Láng, I
    Nitz, U
    Iwata, H
    Thomssen, C
    Lohrisch, C
    Suter, TM
    Ruschoff, J
    Süto, T
    Greatorex, V
    Ward, C
    Straehle, C
    McFadden, E
    Dolci, MS
    Gelber, RD
    NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (16): : 1659 - 1672
12345